GA

What's NEW: 2024 Lexus RX

Retrieved on: 
Tuesday, August 8, 2023
Dark, E-four, Macpherson, Travel, Aluminium, USB, Headlamp, Lighting, POI, Acceleration, Interior, Heat, AVS, Adaptive cruise control, The White Pearl, Maintenance, Miles per gallon gasoline equivalent, LC, Smartphone, Torque, Service, G, Human, GA, Lexus, LS, EPA, Intelligence, AWD, High-output heart failure, Multimedia, AC, LTA, Tablet, RSA, PVM, Radar, PCS, MID, Glass, Macadamia, NX, Black Cascade, DC, HEV, RX, LDA, PDA, Rigidity, DRS, Quantum logic, Electric motor, Telescopic sight, Hydraulic machinery, Rail transport, Television, Mobile phone, Online shopping, Internet service provider, Road, Iridium, Caviar

The 2024 RX rides atop the GA-K platform, which was designed to be lighter than the fourth-generation platform.

Key Points: 
  • The 2024 RX rides atop the GA-K platform, which was designed to be lighter than the fourth-generation platform.
  • Powered by a high-capacity lithium-ion battery paired with a 2.5-liter inline 4-cylinder engine (shared with NX), the 2024 RX 450h+ hybrid system has a manufacturer-estimated combined 83 MPGe rating.
  • The RX 450h+ utilizes an electronically controlled, full-time AWD system for a confident, sporty driving experience, led by Lexus Driving Signature vehicle fundamentals.
  • The 2024 Lexus RX comes standard with Lexus Safety System+ 3.0, which provides additional features and an available driver monitor system.

APELLIS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Apellis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, August 8, 2023
Class Action Lawsuit, Professional Services, Legal, Retinal scan, Retina, Injection, P.C, Autoimmunity, APLS, Telephone, Retinal vasculitis, Clinical trial, Geographic atrophy, Jeanne Eagels, Vasculitis, Paratriathlon, Risk, GA, Inflammation, Person, First, Wedbush Securities, District court, Patient, Physician, Complaint, Court, Regulation of tobacco by the U.S. Food and Drug Administration, Society, News, Food, ASRS, Safety, Pharmaceutical industry

Investors have until October 2, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until October 2, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Apellis is a commercial-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
  • SYFOVRE is designed to provide comprehensive control of the complement cascade, part of the body’s immune system.
  • Apellis also stated that the company is evaluating an eighth reported event of retinal vasculitis, which Apellis had not yet confirmed.

Peach State Health Plan and the Medical College of Georgia at Augusta University Announce 2023 Peach State Scholars

Retrieved on: 
Monday, August 7, 2023
Partnership, Emergency medicine, Augusta University, Centene Corporation, Medical college, Ageing, Medical College of Georgia, GA, Doctor of Philosophy, Student, Retirement, Physician, Internal medicine, Psychiatry, 157th Georgia General Assembly, Nursing

ATLANTA, Aug. 7, 2023 /PRNewswire/ -- Last week, leaders from Peach State Health Plan, a care management organization that serves the needs of Georgians through a range of health insurance solutions and wholly owned subsidiary of Centene Corporation, and the Medical College of Georgia at Augusta University, announced the 2023 "Peach State Scholars." The nine medical students were announced during an official pinning ceremony held at Augusta University. The students are the third class of Peach State Scholars participating in the Medical College of Georgia's 3+ Primary Care Pathway Program, a program established in 2021 that focuses on alleviating Georgia's physician shortage.

Key Points: 
  • The students are the third class of Peach State Scholars participating in the Medical College of Georgia's 3+ Primary Care Pathway Program, a program established in 2021 that focuses on alleviating Georgia's physician shortage.
  • "Our partnership with Peach State Health Plan has been critical to getting the MCG3+ Primary Care Pathway Program off the ground to address Georgia's doctor shortages," said Augusta University President Brooks A.
  • "We have been proud to support the MCG3+ Primary Care Pathway program since its inception and are excited to see it expand into its third year with the 2023 Peach State Scholars," said Peach State Health Plan CEO, Wade Rakes.
  • The 2023 Peach State Scholars, their hometowns and intended specialty are as follows:
    Christopher "Chris" Dick of Dunwoody, GA, Internal Medicine
    Brianna "Taylor" Nicholson of Suwanee, GA, Psychiatry

Latest news - Next DROI meeting - 7 September 2023 - Subcommittee on Human Rights

Retrieved on: 
Monday, August 7, 2023
Home, HU, MT, LV, SK, DROI, FR, PL, Member of the European Parliament, FI, Employment, Cancer, Human rights, European, EN, Artificial intelligence, Tourism, News, Open data portal, Budget, Democrat, SL, GA, Committee, RO, EP, Culture, Rural development, COVID-19, Parliament, LT, DE, Public health, Danish, Contract, Research, Justice, European Parliament, Food safety, EL, CS, PT, Publication, SV, DA, BG, Education, European Parliament Subcommittee on Human Rights, Customer service, Online shopping, Furniture, Typesetting, Airline, Cosmetics, Consumer electronics, Construction, Whaling, Car rental, Publishing, Employment agency, Dairy, Tax advisor, Livestock, Vaccine, Information technology, Residential care, Holding company, Fair, Rare-earth element, Pegasus, Animal

Access to page content (press "Enter")

Key Points: 
  • Access to page content (press "Enter")
    Direct access to language menu (press "Enter")
    Direct access to search menu (press "Enter")
    EN - English
    BG - български
    ES - español
    CS - čeština
    DA - dansk
    DE - Deutsch
    ET - eesti keel
    EL - Ελληνικά
    EN - English
    FR - français
    GA - Gaeilge
    HR - hrvatski
    IT - italiano
    LV - latviešu valoda
    LT - lietuvių kalba
    HU - magyar
    MT - Malti
    NL - Nederlands
    PL - polski
    PT - português
    RO - română
    SK - slovenčina
    SL - slovenščina
    FI - suomi
    SV - svenska
    News
    MEPs
    About Parliament
    Plenary
    Committees
    Delegations
    Other websites
    Other websites
    News
    MEPs
    About Parliament
    Plenary
    Committees
    Delegations
    Multimedia Centre
    President’s website
    Secretariat-general
    Think tank
    EP Newshub
    At your service
    Visits
    Legislative train
    Contracts and Grants
    Register
    Open Data Portal
    Committees
    European Parliament
    Search
    Search
    Please fill this field
    DROI
    European Parliament
    Search
    Menu
    Choose your committee
    Choose your committee
    All committees - Homepage
    Foreign Affairs
    Human Rights
    Security and Defence
    Development
    International Trade
    Budgets
    Budgetary Control
    Economic and Monetary Affairs
    Tax Matters
    Employment and Social Affairs
    Environment, Public Health and Food Safety
    Public Health
    Industry, Research and Energy
    Internal Market and Consumer Protection
    Transport and Tourism
    Regional Development
    Agriculture and Rural Development
    Fisheries
    Culture and Education
    Legal Affairs
    Civil Liberties, Justice and Home Affairs
    Constitutional Affairs
    Women’s Rights and Gender Equality
    Petitions
    Beating Cancer
    COVID-19 pandemic: lessons learned and recommendations for the future
    Special Committee on foreign interference and disinformation, and on strengthening integrity in the EP
    Foreign Interference in all Democratic Processes in the European Union, including Disinformation
    Artificial Intelligence in a Digital Age
    Protection of Animals during Transport
    Use of Pegasus and equivalent surveillance spyware
    Go to the page
    DROI
    Home
    Highlights
    Members
    Press releases
    Publications
    Subject files
    Meetings
    Meeting documents
    Webstreaming
    Votes
    Minutes
    Documents
    Latest documents
    Search
    Work in progress
    Events
    Hearings
    Workshops
    Meetings with National Parliaments
    Supporting analyses
    Latest documents
    Search
    Presentation
    Outreach
    About
    Go back
    DROI
    Home
    Highlights
    Next DROI meeting - 7 September 2023
    Next DROI meeting - 7 September 2023
    07-08-2023 - 11:37
    Share this page on Facebook
    Share this page on Twitter
    Share this page on LinkedIn
    The next meeting of the Subcommittee on Human Rights will be held on
    Thurs
    day, 7 September 2023, 9.00-12.00 in room SPINELLI 5G3.
  • DROI Meetings 2023
    Urgency Resolutions on human rights

Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy

Retrieved on: 
Saturday, August 5, 2023
Food, AMD, Geographic atrophy, FDA, Astellas Pharma, Regulation of tobacco by the U.S. Food and Drug Administration, TSE, GA, C5, Electric battery, Pharmaceutical industry

TOKYO, Aug. 5, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today announced the U.S. Food and Drug Administration (FDA) approved IZERVAY™ (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) on August 4, 2023. IZERVAY, a new complement C5 inhibitor, is the only approved GA treatment with a statistically significant reduction (p

Key Points: 
  • We would like to thank everyone involved in reaching this milestone and helping us deliver on our commitment to pioneer transformational therapies for retinal diseases."
  • Slowing of disease progression was observed as early as 6 months with up to a 35% reduction in the first year of treatment.
  • This new treatment offers our patient community an important therapeutic option to potentially extend their ability to maintain independence."
  • Astellas is reviewing potential financial impacts of this approval for the fiscal year ending March 31, 2024.

APELLIS PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)

Retrieved on: 
Friday, August 4, 2023
Injection, LLP, APLS, Class, Retinal vasculitis, Geographic atrophy, Paratriathlon, Risk, GA, District court, Patient, Advertising, Complaint, Court, Defendant, Action Replay, Regulation of tobacco by the U.S. Food and Drug Administration, Society, News, Food, Autoimmunity, Inflammation, Pharmaceutical industry, Security (finance)

Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the common stock of Apellis Pharmaceuticals Inc. (“Apellis” or the “Company”) (NASDAQ: APLS) between January 28, 2021 and July 28, 2023, inclusive (the “Class Period”).

Key Points: 
  • Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the common stock of Apellis Pharmaceuticals Inc. (“Apellis” or the “Company”) (NASDAQ: APLS) between January 28, 2021 and July 28, 2023, inclusive (the “Class Period”).
  • If you purchased or acquired Apellis common stock, and/or would like to discuss your legal rights and options please visit Apellis Pharmaceuticals, Inc.
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] .
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Apellis Pharmaceuticals, Inc. (APLS)

Retrieved on: 
Thursday, August 3, 2023
Injection, APLS, Retinal vasculitis, Geographic atrophy, Paratriathlon, Risk, GA, Person, District court, Patient, Complaint, Immune system, Solar eclipse of October 2, 1959, Regulation of tobacco by the U.S. Food and Drug Administration, NYSE, Food, Pharmaceutical industry

SYFOVRE is designed to provide comprehensive control of the complement cascade, part of the body's immune system.

Key Points: 
  • SYFOVRE is designed to provide comprehensive control of the complement cascade, part of the body's immune system.
  • The clinical trials designed by Apellis for its SYFOVRE therapeutic treatment failed to identify cases of retinal vasculitis in patients receiving injections.
  • If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq.
  • of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected] .

Tetrate Service Express Now Generally Available in AWS Marketplace

Retrieved on: 
Thursday, August 3, 2023
NIST, Amazon Web Services, Information, VM, Amazon Route 53, Education, Ford Torino engine specifications, GA, MIT, Massachusetts Institute of Technology, Organization, Amazon, ZTA, IS, Running, National Institute of Standards and Technology, SAN, Tetration, IS&T, AWS, DevOps, IEEE 802.1X, EKS, TSE, Online shopping

SAN FRANCISCO, Aug. 3, 2023 /PRNewswire-PRWeb/ -- Tetrate, the company solving application networking and security for enterprises, today announced the general availability (GA) of Tetrate Service Express (TSE). The new platform is designed for enterprises using Amazon Elastic Kubernetes Service (Amazon EKS) that want to use cloud-native and open source Istio and Envoy Proxy.

Key Points: 
  • SAN FRANCISCO, Aug. 3, 2023 /PRNewswire-PRWeb/ -- Tetrate, the company solving application networking and security for enterprises, today announced the general availability (GA) of Tetrate Service Express (TSE) .
  • TSE is now available in AWS Marketplace , a digital catalog with thousands of software listings from independent software vendors that make it easy to find, test, buy and deploy software that runs on Amazon Web Services (AWS).
  • TSE provides a fast, proven path for new users to get started with Istio-powered service mesh in minutes on Amazon EKS.
  • "Solutions like Tetrate Service Express will dramatically accelerate how organizations can innovate and bring creative solutions to market."

Deepfence Unleashes ThreatStryker, the Enterprise Evolution of Open Source Cloud-Native Application Protection Platform

Retrieved on: 
Thursday, August 3, 2023
Cloud, GitHub, UI, Noise, Engineering, GA, Information, Amazon, Software, EC2, Map, Payment, Organization, Risk management, Online shopping

SAN FRANCISCO, Aug. 3, 2023 /PRNewswire/ -- Deepfence, a leader in cloud-native security, today announced the General Availability of ThreatStryker, Enterprise offering built on top of ThreatMapper, the most widely deployed Cloud Native Application Protection Platform (CNAPP) on the market. Deepfence's CNAPP has shown tremendous momentum in the market, amassing over 10,000 stars on GitHub across Deepfence's open source product portfolio and is used by 3,000 enterprises worldwide.

Key Points: 
  • Deepfence's CNAPP has shown tremendous momentum in the market, amassing over 10,000 stars on GitHub across Deepfence's open source product portfolio and is used by 3,000 enterprises worldwide.
  • "Deepfence has changed the economic landscape of cloud security with our open source first strategy which insists that companies shouldn't have to pay to know what the security posture of their internal attack surface looks like," Sandeep Lahane, CEO of Deepfence said.
  • Deepfence has built on that open source momentum and extended the feature set of ThreatStryker with advanced eBPFGuard technology to offer runtime protection and inline threat neutralization that stops threat actors in their tracks in real time.
  • Get started with the open source or enterprise versions of Deepfence for free.

Complement Therapeutics Appoints Dr Parisa Zamiri MD, as Chief Medical Officer

Retrieved on: 
Thursday, August 3, 2023
Parisa, University, University of London, Therapy, Doctor of Philosophy, Smith-Kettlewell Eye Research Institute, AMD, Pharmacovigilance, Retinitis pigmentosa, Quality of life, Geographic atrophy, Hope, Statistics, GA, CMO, King's College Hospital, Gesellschaft mit beschränkter Haftung, Harvard Medical School, Ophthalmology, Novartis, Massachusetts Eye and Ear, Patient, CTX, Schepen, Ear, Pharmaceutical industry, Medical device

MUNICH, Aug. 3, 2023 /PRNewswire/ -- Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the appointment of Dr Parisa Zamiri as its Chief Medical Officer, effective immediately.

Key Points: 
  • MUNICH, Aug. 3, 2023 /PRNewswire/ -- Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the appointment of Dr Parisa Zamiri as its Chief Medical Officer, effective immediately.
  • Dr. Zamiri joins CTx from Graybug Vision, Inc., where she held the position of Chief Medical Officer and was responsible for all clinical, statistics, regulatory and medical affairs activities, successfully completing phase II development of their lead asset for wet age-related macular degeneration.
  • "We are excited to welcome Parisa to the CTx team as CMO," said Dr Rafiq Hasan, Chief Executive Officer.
  • said Dr Parisa Zamiri, Chief Medical Officer.